[Osteolytic destruction as leading symptom of Kaposi's sarcoma].
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D006957:Hyperostosis Frontalis Interna / Q000209:etiology*; D012514:Sarcoma, Kaposi / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D012877:Skin Manifestations
D000970:Antineoplastic Agents
Osteolytische Destruktion als Leitsymptom des Kaposi-Sarkoms.